Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value

English version České info

Background:
Colon cancer (CC) pathological staging fails to accurately predict recurrence, and to date, no gene expression signature has proven reliable for prognosis stratification in clinical practice, perhaps because CC is a heterogeneous disease. The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses.

Methods and Findings:
Fresh-frozen primary tumor samples from a large multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers were characterized for common DNA alterations, including BRAF, KRAS, and TP53 mutations, CpG island methylator phenotype, mismatch repair status, and chromosomal instability status, and were screened with whole genome and transcriptome arrays. 566 samples fulfilled RNA quality requirements. Unsupervised consensus hierarchical clustering applied to gene expression data from a discovery subset of 443 CC samples identified six molecular subtypes. These subtypes were associated with distinct clinicopathological characteristics, molecular alterations, specific enrichments of supervised gene expression signatures (stem cell phenotype–like, normal-like, serrated CC phenotype–like), and deregulated signaling pathways. Based on their main biological characteristics, we distinguished a deficient mismatch repair subtype, a KRAS mutant subtype, a cancer stem cell subtype, and three chromosomal instability subtypes, including one associated with down-regulated immune pathways, one with up-regulation of the Wnt pathway, and one displaying a normal-like gene expression profile. The classification was validated in the remaining 123 samples plus an independent set of 1,058 CC samples, including eight public datasets. Furthermore, prognosis was analyzed in the subset of stage II–III CC samples. The subtypes C4 and C6, but not the subtypes C1, C2, C3, and C5, were independently associated with shorter relapse-free survival, even after adjusting for age, sex, stage, and the emerging prognostic classifier Oncotype DX Colon Cancer Assay recurrence score (hazard ratio 1.5, 95% CI 1.1–2.1, p = 0.0097). However, a limitation of this study is that information on tumor grade and number of nodes examined was not available.

Conclusions:
We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA markers. The biological relevance of these subtypes is illustrated by significant differences in prognosis. This analysis provides possibilities for improving prognostic models and therapeutic strategies. In conclusion, we report a new classification of CC into six molecular subtypes that arise through distinct biological pathways.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. PLoS Med 10(5): e32767. doi:10.1371/journal.pmed.1001453
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001453

Souhrn

Zdroje

1. GreenleeRT, MurrayT, BoldenS, WingoPA (2000) Cancer statistics, 2000. CA Cancer J Clin 50: 7–33.

2. American Joint Committee on Cancer (1997) AJCC cancer staging manual, 5th edition. Philadelphia: Lippincott-Raven.

3. PopatS, HubnerR, HoulstonRS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609–618.

4. HutchinsG, SouthwardK, HandleyK, MagillL, BeaumontC, et al. (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29: 1261–1270.

5. WangY, JatkoeT, ZhangY, MutchMG, TalantovD, et al. (2004) Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22: 1564–1571.

6. EschrichS, YangI, BloomG, KwongKY, BoulwareD, et al. (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23: 3526–3535.

7. SalazarR, RoepmanP, CapellaG, MorenoV, SimonI, et al. (2011) Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29: 17–24.

8. O'ConnellMJ, LaveryI, YothersG, PaikS, Clark-LangoneKM, et al. (2010) Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28: 3937–3944.

9. JassJR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50: 113–130.

10. ShenL, ToyotaM, KondoY, LinE, ZhangL, et al. (2007) Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104: 18654–18659.

11. KangGH (2011) Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med 135: 698–703.

12. HinoueT, WeisenbergerDJ, LangeCP, ShenH, ByunHM, et al. (2012) Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 22: 271–282.

13. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330–337.

14. LièvreA, BachetJB, BoigeV, CayreA, Le CorreD, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374–379.

15. CabelguenneA, BlonsH, de WaziersI, CarnotF, HoullierAM, et al. (2000) p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18: 1465–1473.

16. BolandCR, ThibodeauSN, HamiltonSR, SidranskyD, EshlemanJR, et al. (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248–5257.

17. WeisenbergerDJ, SiegmundKD, CampanM, YoungJ, LongTI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787–793.

18. de ReynièsA, AssiéG, RickmanDS, TissierF, GroussinL, et al. (2009) Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27: 1108–1115.

19. IrizarryRA, BolstadBM, CollinF, CopeLM, HobbsB, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.

20. JohnsonWE, LiC, RabinovicA (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118–127.

21. GuedjM, MarisaL, de ReyniesA, OrsettiB, SchiappaR, et al. (2012) A refined molecular taxonomy of breast cancer. Oncogene 31: 1196–1206.

22. MontiS, TamayoP, MesirovJ, GolubT (2003) Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn 52: 91–118.

23. SorlieT, TibshiraniR, ParkerJ, HastieT, MarronJS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418–8423.

24. Merlos-SuárezA, BarrigaFM, JungP, IglesiasM, CéspedesMV, et al. (2011) The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8: 511–524.

25. KosinskiC, LiVS, ChanAS, ZhangJ, HoC, et al. (2007) Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci U S A 104: 15418–15423.

26. PopoviciV, BudinskaE, TejparS, WeinrichS, EstrellaH, et al. (2012) Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 30: 1288–1295.

27. LaihoP, KokkoA, VanharantaS, SalovaaraR, SammalkorpiH, et al. (2007) Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 26: 312–320.

28. SnoverDC (2011) Update on the serrated pathway to colorectal carcinoma. Hum Pathol 42: 1–10.

29. LiangJJ, BissettI, KaladyM, BennetA, ChurchJM (2012) Importance of serrated polyps in colorectal carcinogenesis. ANZ J Surg E-pub ahead of print. doi:10.1111/j.1445-2197.2012.06269.x.

30. AlfaroMP, PagniM, VincentA, AtkinsonJ, HillMF, et al. (2008) The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci U S A 105: 18366–18371.

31. OhSC, ParkYY, ParkES, LimJY, KimSM, et al. (2011) Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 61: 1291–1298.

32. LinYH, FriederichsJ, BlackMA, MagesJ, RosenbergR, et al. (2007) Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 13: 498–507.

33. Salazar R, Tabernero J, Moreno V, Nitsche U, Bachleitner-Hofmann T, et al.. (2012) Validation of a genomic classifier (ColoPrint) for predicting outcome in the T3-MSS subgroup of stage II colon cancer patients [abstract 3510]. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago, Illinois, US.

34. (2011) A prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint (PARSC). ClinicalTrials.gov: NCT00903565. Available: http://clinicaltrials.gov/ct2/show/NCT00903565. Accessed 16 April 2013.

35. GrayRG, QuirkeP, HandleyK, LopatinM, MagillL, et al. (2011) Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29: 4611–4619.

36. VenookAP, NiedzwieckiD, LopatinM, LeeM, FriedmanPN, et al. (2011) Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581 [abstract]. 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 29(May 20 Suppl): 3518.

37. O'ConnellM, LeeM, LopatinM, YothersG, Clark-LangoneK, et al. (2012) Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox) [abstract]. 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 30(May 20 Suppl): 3512.

38. Roth A, Di Narzo AF, Tejpar S, Bosman F, Popovici V, et al.. (2012) Validation of two gene-expression risk scores in a large colon cancer cohort and contribution to an improved prognostic method [abstract 3509]. American Society of Clinical Oncology Annual Meeting; 1–5 Jun 2012; Chicago, Illinois, US.

39. WeiserMR, GönenM, ChouJF, KattanMW, SchragD (2011) Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol 29: 4796–4802.